Blue Jet Healthcare breaks ground on Rs. 2,300 crore pharma plant in Andhra Pradesh
The facility is expected to become operational by FY2028-29
The facility is expected to become operational by FY2028-29
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
Subscribe To Our Newsletter & Stay Updated